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Abstract
Background Recent data confirmed the importance of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-
PET) in the selection of patients with colorectal hepatic metastases for surgery. Neoadjuvant chemotherapy before hepatic
resection in selected cases may improve outcome. The influence of chemotherapy on the sensitivity of FDG-PET and CT in
detecting liver metastases is not known.
Methods Patients were assigned to either neoadjuvant treatment or immediate hepatic resection according to resectability,
risk of recurrence, extrahepatic disease, and patient preference. Two-thirds of them underwent FDG-PET/CT before
chemotherapy; all underwent preoperative contrast-enhanced CT and FDG-PET/CT. Those without extensive extrahepatic
disease underwent open exploration and resection of all the metastases according to original imaging findings. Operative
and pathological findings were compared to imaging results.
Results Twenty-seven patients (33 lesions) underwent immediate hepatic resection (group 1), and 48 patients (122 lesions)
received preoperative neoadjuvant chemotherapy (group 2). Sensitivity of FDG-PET and CT in detecting colorectal (CR)
metastases was significantly higher in group 1 than in group 2 (FDG-PET: 93.3 vs 49%, P<0.0001; CT: 87.5 vs 65.3, P=
0.038). CT had a higher sensitivity than FDG-PET in detecting CR metastases following neoadjuvant therapy (65.3 vs 49%,
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Tel-Aviv, IsraelP<0.0001). Sensitivity of FDG-PET, but not of CT, was lower in group 2 patients whose chemotherapy included
bevacizumab compared to patients who did not receive bevacizumab (39 vs 59%, P=0.068).
Conclusions FDG-PET/CT sensitivity is lowered by neoadjuvant chemotherapy. CT is more sensitive than FDG-PET in
detecting CR metastases following neoadjuvant therapy. Surgical decision-making requires information from multiple
imaging modalities and pretreatment findings. Baseline FDG-PET and CT before neoadjuvant therapy are mandatory.
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Introduction
The liver is the most common, and often the only, site of
distant metastases from colorectal cancer (CRC).
1 Hepatic
resection is the only effective therapy for a subset of
patients with CRC metastatic to the liver, and is associated
with 5-year survival rates ranging from 25 to 40%.
2–5 From
60 to 65% of patients will, however, develop recurrent
tumors after hepatic resection, indicating that they had
harbored unrecognized intra- or extrahepatic tumor foci at
the time of liver resection.
6 Moreover, several studies report
unresectable disease in 40–70% of patients that undergo
laparotomy for liver resection.
2,7,8 These data indicate that
better patient selection is needed to avoid unnecessary
operations. There are several potential ways of improving
patient selection, one of which is the administration of
neoadjuvant therapy followed by reevaluation and better
preoperative staging.
Positron emission tomography with the glucose analog
18-fluoro-2-deoxy-D-glucose (FDG-PET) is a sensitive
diagnostic tool for the detection of colorectal metastases.
Approximately 25% of patients are discovered to have new
intra- or extrahepatic tumors on FDG-PET performed after
standard imaging.
9–13 Screening with FDG-PET before
hepatic resection for CRC significantly improves the
survival rates of resected patients, probably by improving
patient selection.
14
The role of neoadjuvant chemotherapy to down-stage
nonresectable liver metastases and to improve outcome
following hepatic resection of resectable liver metastases
is an evolving concept, but one that is not yet estab-
lished. With the recent application of new chemothera-
peutic agents, such as irinotecan, oxaliplatin, and
bevacizumab, improved response rates can be achieved
and the use of these agents in the neoadjuvant setting
would appear to be especially relevant for patients with
nonresectable disease or patients with high risk of
recurrence.
15–18
The aim of our study was to examine the effect of
neoadjuvant chemotherapy for hepatic colorectal metastases
o nC Ta n dF D G - P E T / C Tf i n d i n g sa n dt od e f i n et h er o l eo f
these imaging techniques in this setting. To do so, we compared
CT and FDG-PET/CT findings with histopathological reports.
Patients and Methods
Patients
Patients with colorectal liver metastases were assigned to
receive either an immediate liver resection (group 1) or
neoadjuvant chemotherapy (group 2). The criteria for
neoadjuvant treatment were:
1. Nonresectable tumors due to size, location, and number
and assessment of the surgical team that complete (R0)
resection was not technically possible.
2. High risk of recurrence according to the Memorial
Sloan–Kettering Cancer Center (MSKCC) clinical risk
score to assess risk of recurrence.
19 Specifically,
patients with two or more risk factors [number of
metastases >1, disease-free survival <12 months, carci-
noembryonic antigen (CEA) levels >200 ng/ml, metas-
tases from the colonic tumor to regional lymph nodes,
size of the largest metastases >5 cm] were assigned to
neoadjuvant treatment.
3. Presence of extrahepatic disease.
4. Oncologist’s preference—this applied to patients with
MSKCC >2 that were referred from other hospitals for
immediate surgery. The decision not to administer
neoadjuvant therapy was not necessarily in agreement
with our policy.
5. Patient’s preference—patients who refused neoadjuvant
therapy were assigned to immediate surgery when feasible.
Neoadjuvant Chemotherapy
Treatment consisted of a neoadjuvant chemotherapeutic
combination of 5-fluorouracil, leucovorin, and either oxalipla-
tin (FOLFOX) or irinotecan (FOLFIRI). Seventeen patients
(35%) were also given bevacizumab. Most of the group 2
patients were given neoadjuvant irinotecan unless they were
enrolled on a multicenter study whose protocol consisted of
the administration of neoadjuvant oxaliplatin.
Staging
Before undergoing neoadjuvant chemotherapy, all group 2
patientsunderwentatriphasiccontrast-enhancedCTscan,and
a FDG-PET/CTwas performed in 30 (62.5%) of them. All 75
patients in group 1 and group 2 underwent FDG-PET/CTand
abdominal CT before liver surgery. The time interval between
the last course of chemotherapy and the FDG-PET/CT scan
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within 1 month following the FDG-PET/CT scan in most of
the cases. Because we used an integrated PET/CT technique,
precise anatomical localization could be achieved and
confirmed with the standard triphasic abdominal CT findings.
PET/CT
The patients were asked to fast for at least 4 h before
undergoing PET/CT. Earlier lab tests had shown that they
all had glucose levels <150 mg%. The patients received an
intravenous injection of 370–666 MBq (10–18 mCi) of
18F-
FDG. Data acquisitions by an integrated PET/CT system
(Discovery LS; GE Medical Systems, Milwaukee, WI, USA)
were performed within 60–120 min after injection. Iodinated
oral contrast material was given to opacify loops of the bowel
ontheCTimage.Dataacquisitionwasasfollows:CTscanning
was performed first, from the head to the pelvic floor, with
140 kV, 80 mA, a tube rotation time of 0.5 s, a pitch of 6, and a
5-mmsectionthickness,whichwasmatchedtothePETsection
thickness.ImmediatelyafterCTscanning,aPETemissionscan
thatcoveredtheidenticaltransversefieldofviewwasobtained.
Acquisition time was 5 min per table position. PETimage data
sets were reconstructed iteratively by applying the CT data for
attenuation correction,and coregistered images were displayed
on a workstation (Xeleris, Elgems, Haifa, Israel).
Studies of all patients were retrieved and read in
consensus by two experts (U.M. and E.E.-S.). All suspected
sites of metastatic disease showing an increased FDG uptake
were recorded. The location of hepatic lesions was recorded
according to the Couinaud segmental classification.
Hepatectomy
All patients without extensive extrahepatic disease under-
went surgical exploration and intraoperative ultrasound
(IOUS). Resections of all metastatic sites were performed
by either anatomic or R0 nonanatomic resection, with a
tendency toward maximal parenchymal preservation with
nonanatomic resections.
Complete radiological response to neoadjuvant chemo-
therapy was defined as the complete resolution of all
metastatic sites according to the CT and PET-CT. In these
cases, careful palpation and IOUS were performed in search
of remaining tumor or scarring. When there was no
evidence of either, the tumor sites were resected according
to the findings on the original imaging (i.e., before any
response to neoadjuvant treatment).
Detection of Hepatic Metastases
To define the sensitivity of CT and FDG-PET/CT for liver
metastases, imaging results were compared with the
presence and size of liver lesions as demonstrated and
measured by histopathological reports.
Results
Patients
Between June 2002 and September 2005, 75 patients with
155 suspected metastatic lesions from a primary CRC
underwent hepatic resection in our department. Group 1
included 27 patients with 33 lesions who underwent
immediate liver resection and group 2 included 48 patients
with 122 lesions who first received neoadjuvant chemother-
apy before subsequently undergoing liver resection. The
patient’s profiles are outlined in Table 1. Table 2 lists the
operative procedures that were performed in the two groups.
Detection of Hepatic Metastases
The overall findings, the sensitivity, specificity, and
accuracy of triphasic contrast-enhanced CT and FDG-
PET/CT in the detection of viable liver metastases
compared to the pathological results are presented in
Table 3. FDG-PET and CT had a statistically significant
higher sensitivity in detecting liver metastases in patients
who did not receive chemotherapy compared to patients
who received chemotherapy (Table 3). Statistical analysis
also revealed that triphasic contrast-enhanced CT had a
Table 1 Study Patients’ Profiles
Group 1
(n=27)
Group 2
(n=48)
P
value
Sex ratio (F/M) 0.50 0.92 0.22
Mean age, years
(std deviation)
66 (9.8) 61.25
(10.9)
0.06
Site
Colon 9 (71%) 32 (66%) 0.74
Rectum 8 (29%) 16 (33%)
LN metastases (Duke’s> B
in colonic specimen)
81.5% 82% 0.73
No. of liver tumors (mean)
(std deviation)
1.19 (0.4) 2.52 (1.9) 0.0001
Max tumor diameter (largest)
(std deviation)
3.53 cm
(2.84)
3.9 cm
(1.84)
0.49
Extrahepatic disease
(no. of patients)
7 9 0.56
Prior liver resection 4 6 1
Mean MSKCC risk score
(range)
1.82
(0–4)
2.48
(2–5)
0.003
Group 1, immediate hepatic resection; Group 2, hepatic resection
following neoadjuvant chemotherapy
LN=lymph node
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metastasis following neoadjuvant treatment (65.3 vs 49%,
respectively, P<0.0001), but not in patients who did not
receive neoadjuvant therapy (87.5 vs 93.3%, P=0.625).
Four of the six false-positive (FP) results on FDG-PET
involved patients who had previously undergone hepatic
resection. These lesions were discovered on follow-up FDG-
PET/CT. Uptake was observed along the resection site, and
these patients underwent nonanatomic liver resections for
suspected locally recurrent lesions. Pathologic evaluation
failed to reveal any tumor cells. The positive predictive value
of FDG-PET/CT for metastasis recurrence in the resection
site was only 33%, and specificity was 60%.
Sensitivity of FDG-PET in the detection of colorectal
metastasis correlated with the size of the metastasis
(Table 4). Average size of the metastases in the two groups
was 33.9 mm (standard deviation 19) in group 1 and
18.9 mm (standard deviation 19) in group 2, P<0.0001.
We also compared the sensitivity of CT and FDG-PET
for patients who received FOLFIRI or FOLFOX (n=31)
with patients who received the same regimen plus bev-
acizumab (n=17). The results are outlined in Table 5.W e
found that the sensitivity of FDG-PET, but not of CT, was
lower in patients who received bevacizumab, although the
difference did not reach statistical significance.
Detection of Extrahepatic Metastases
In group 1, there were one FP result for extrahepatic disease
(suspected recurrence in colonic anastomosis, abdominal
wall), one true-positive (TP) result (recurrence in mesocolic
lymph nodes), and one false negative (FN) result (in a patient
with peritoneal metastases). In group 2, there was one FP
result (for suspected peritoneal metastasis), three TP results
(recurrence in paraaortic lymph nodes and solitary lung
metastasis), and two FN results (for peritoneal metastases).
Discussion
The role of neoadjuvant chemotherapy followed by
hepatectomy for colorectal liver metastases has not yet
been clearly established. New chemotherapeutic agents,
including irinotecan, oxaliplatin, and the biologic agent
bevacizumab, have yielded improved response rates in the
treatment of advanced CRC. These agents may have a
potential role in the neoadjuvant setting for down-staging
both nonresectable disease to resectability
15,16 and resect-
able disease, probably mostly for patients with high risk of
recurrence.
17 Our policy is to administer neoadjuvant
treatment to patients with nonresectable disease, those with
extrahepatic disease, and those with resectable disease who
have two or more risk factors according to the MSKCC
clinical risk score.
19 One of the theoretical benefits of
neoadjuvant treatment is that patients who develop addi-
tional extrahepatic or intrahepatic metastases during this
time period are spared a futile major operative procedure.
Accurate staging before the beginning of neoadjuvant
treatment and restaging following the treatment are crucial
for optimal patient selection.
The standard preoperative staging of patients with
colorectal liver metastases includes combined abdominal
CT and chest x-ray or chest CT. It was recently demon-
strated that FDG-PET as a complementary staging method
improves the therapeutic management of patients with
colorectal liver metastases.
20 Preoperative screening with
FDG-PET results in an increased survival rate of patients
who undergo liver resection.
14 This can be explained by the
Table 2 Operative Procedures
Operative procedure
(no. of patients; lesions)
Group 1
(n=27)
Group 2
(n=48)
Right hepatic lobectomy 5 8
Left hepatic lobectomy 4 4
Central hepatectomy 0 3
Right trisegmentectomy 1 0
Nonanatomic resections 15 29
Left lat segmentectomy 2 2
Explorative laparotomy (no resection) 0 2
Group 1, immediate hepatic resection; Group 2, hepatic resection
following neoadjuvant chemotherapy
Table 3 FDG-PET and CT—Comparison With Pathological Results
Group 1
n=33
Group 2
n=122
P value
PET
TP 29 48
True negative
(complete response)
– 20
FP 2 4
FN 2 50
Sensitivity 93.3% 49% <0.0001
Specificity – 83.3%
CT
TP 28 64
True negative
(complete response)
– 18
FP 1 6
FN 4 34
Sensitivity 87.5% 65.3% 0.038
Specificity – 75%
Group 1, immediate hepatic resection; group 2, hepatic resection
following neoadjuvant chemotherapy
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disease, thus obviating futile explorations. In the current
study, the sensitivity of FDG-PET/CT following neoadju-
vant therapy was only 49% compared to a sensitivity of
93.3% in patients who did not receive neoadjuvant
treatment (P<0.0001). The influence of the chemothera-
peutic drugs on the sensitivity of FDG-PET in detecting
extrahepatic metastases is not known, but we could assume
that it is influenced in a similar way. This may result in a
higher-than-expected rate of nonresectable disease discov-
ered at the time of laparotomy and more extrahepatic
recurrences following resection. In our series, only three of
the 48 patients (6.25%) who received neoadjuvant chemo-
therapy were found to have nonresectable disease (one had
diffuse liver metastases and two had peritoneal spread) that
was not discovered preoperatively by either abdominal CT
or FDG-PET/CT. We believe that one of the reasons for the
high operability rate is the fact that a significant number of
patients underwent a baseline FDG-PET/CT before the
administration of neoadjuvant chemotherapy. We therefore
recommend performing a baseline FDG-PET scan for all
candidates for liver resection before the administration of
neoadjuvant treatment. A longer follow-up is needed to
assess the results of our application of this protocol.
The decreased sensitivity of FDG-PET/CT in detecting
liver metastases should also be a consideration when planning
the extent of liver resection. We believe that the extent of
resection should be guided by additional imaging modalities,
including abdominal CT and IOUS, in patients who received
neoadjuvant treatment. In our series, triphasic contrast-
enhanced abdominal CT had a higher sensitivity than FDG-
PET/CT in detecting colorectal metastasis in patients who
received neoadjuvant chemotherapy (65.3 vs 49%, P<
0.0001). The higher sensitivity of CT alone compared to
FDG-PET/CT in detecting small colorectal metastasis has
been reported by Ruers et al.,
20 and this may be even greater
in patients who received chemotherapy. An attractive
solution is the integrated PET/CT scanner on which a
diagnostic triphasic abdominal CT scan can be performed
at the same setting as the PET scan.
There are several possible explanations for the decreased
sensitivity of FDG-PET/CT in the detection of colorectal
metastases following neoadjuvant therapy:
1. Size of the lesion. The sensitivity of FDG-PET in
detecting colorectal metastasis was reported as being
directly related to the size of the lesions.
20 We found
similar results in our series (Table 4). The average size
of the metastases following neoadjuvant treatment was
significantly smaller than that in patients who did not
receive chemotherapy (33.9 mm in group 1 and 18.9 mm
in group 2, P<0.0001). Two FN results in group 1 and
32 in group 2 involved tumors smaller than 1 cm. We
can assume that one of the main reasons for the
decreased sensitivity of FDG-PET following chemo-
therapy is the decrease in size of the metastases.
2. Chemotherapy and “metabolic shutdown.” It has been
demonstrated that the sensitivity of FDG-PET is
diminished in cancer patients who undergo the exam-
ination less than 2 weeks following the administration
of chemotherapy,
21 presumably due to a temporary
metabolic “shutdown.” Although the scans in our study
were done with a minimal interval of 2 weeks from the
last course of chemotherapy, partial response to therapy
may have caused decreased FDG uptake in metastatic
lesions, making them undetectable in comparison to the
physiological background uptake of FDG in the liver.
This may have been a contributing factor to the FN
results in our series. We found a lower sensitivity of
FDG-PET (but not of CT) in detecting liver metastases
following regimens including bevacizumab compared
to regimens that did not include bevacizumab, although
the difference did not reach statistical significance. This
result may have significant clinical implications; how-
ever, it needs to be verified in larger series.
Table 4 Sensitivity of FDG-PET: Correlation With Tumor Size
Tumor size <1 cm 1–3c m > 3c m
Group 1 sensitivity
(total no. of lesions)
33%
(n=3)
100%
(n=15)
92%
(n=13)
Group 2 sensitivity
(total no. of lesions)
17%
(n=35)
78%
(n=41)
100%
(n=22)
Group 1, immediate hepatic resection; group 2, hepatic resection
following neoadjuvant chemotherapy
Table 5 FDG-PET and CT in Patients who Received Chemotherapy
With or Without Bevacizumab: Comparison With Pathological Results
Bevacizumab − Bevacizumab + P
value
PET
TP 29 19
True negative
(complete response)
17 3
FP 2 2
FN 20 30
Sensitivity 59% 39% 0.068
CT
TP 33 31
True negative
(complete response)
13 5
FP 6 0
FN 16 18
Sensitivity 67% 63% 0.9
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series, two patients with FN results (two hepatic lesions)
underwent surgery more than 2 months after FDG-PET
was performed. Viable tumors were discovered at the
site of the original metastases which had disappeared on
FDG-PET following neoadjuvant treatment. Although it
is conceivable that the relatively long interval between
FDG-PET and surgery may have contributed to the FN
results, we believe that these tumors may have been FN
due the small size of the lesions following partial
pathological response to chemotherapy.
4. Nonavid tumors. PET avidity of the tumors can be
assessed only in patients who undergo a baseline FDG-
PET before neoadjuvant treatment. It has been reported
that FDG-PET is less sensitive for mucinous adenocar-
cinoma.
22 In our series, ten FN results (lesions) were in
patients with nonavid mucinous adenocarcinoma (sen-
sitivity 37.5%).
There were two FP results in group 1 and four FP results
in group 2. Four of the six FP results were in patients who
had undergone a previous hepatic resection, for which
follow-up FDG-PET detected uptake in the same location
of the resected metastasis. These patients underwent
nonanatomic resections of the “lesions.” The pathological
examination revealed only foreign body reaction without
any tumor cells. In our current study, FDG uptake in the
tumor bed following previous resection had a positive
predictive value of 33% (2/6). The specificity of FDG
uptake in the tumor bed for recurrence was 60%. We
believe that FDG uptake in the tumor bed following a
previous liver resection is not specific for tumor recurrence,
especially if the CEA levels are normal. Nguyen et al.
demonstrated that FDG uptake may be high in various
granulomatous lesions,
23 possibly explaining the FP results
along resection margins. Therefore, biopsy or follow-up
should be considered in these cases.
Conclusions
The sensitivity of FDG-PET in detecting colorectal hepatic
metastases decreases significantly following neoadjuvant
chemotherapy. This may result in a higher-than-expected
rate of nonresectable disease discovered at the time of
laparotomy and in more extrahepatic recurrences following
resection. We recommend staging patients with a “baseline”
contrast-enhanced FDG-PET/CT both before and after the
administration of neoadjuvant therapy. The extent of
hepatic resection should be guided by systematic integra-
tion of data from all additional imaging modalities
(abdominal CT, IOUS), as well as by the original imaging
findings (before the neoadjuvant treatment). We recom-
mend resection of all metastases that achieved complete
radiological response, whenever technically possible. Lon-
ger follow-up and further studies are required to justify
neoadjuvant treatment and screening with FDG-PET/CT in
patients with colorectal metastases to the liver who are at
high risk of recurrence.
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